Navigation Links
Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
Date:3/23/2009

ifying and securing a primary care marketing partner."

The financial information provided in this press release is for Transcept Pharmaceuticals, Inc., the private corporation that merged with Novacea, Inc. and whose business is substantially the business of the combined public company. The financial results of Transcept for quarter and year ended December 31, 2008 will be filed with the Securities and Exchange Commission (SEC) on Form 8-K on or before March 31, 2009. Financial results of Novacea, Inc. for the quarter and year ended December 31, 2008 will be filed separately on Form 10-K with the SEC.

Full Year 2008 Financial Results

Research and development expenses for the year ended December 31, 2008 were $10.4 million, compared to $15.9 million for 2007. Of this $5.5 million decrease, $4.9 million is attributable to decreased expenses incurred in 2008 as the Phase 3 clinical development program for Intermezzo(R) was substantially completed in 2007. The remaining $0.6 million decrease is attributable to the reduction in expenditures for the Company's earlier stage development programs. Research and development expenses included non-cash stock compensation expense in accordance with Statement of Financial Accounting Standards, or SFAS, No. 123R of $0.3 million for the year ended December 31, 2008 and $0.2 million for the year ended December 31, 2007.

General and administrative expenses for 2008 were $7.9 million, compared to $5.3 million for 2007. Of this $2.6 million increase, approximately $1.7 million is attributable to higher professional fees incurred in preparation for operating as a publicly traded company, and increased headcount and related salary expenses. The remaining $0.9 million is attributable to market research expenses to support the development of the Intermezzo(R) commercialization plan. General and administrative expenses included non-cash stock compensa
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
2. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
3. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
4. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
5. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
10. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... The impact of the Trivedi Master ... of the public and is likely to cause further, ... and June. From March 21st to March 31st, ... "Special Prayers." More than 600 people participated in the ... and have reported intense experiences that they attest have ...
(Date:4/25/2015)... April 25, 2015 The URO CENTER of ... has been chosen by the New York Academy of Medicine ... medicine in the field of Urology. , Dr. Ferdinand Valentine, ... speciality, Genito-Urinary diseases. He was a man of rare ... of urology. Not only did he devote his life ...
(Date:4/24/2015)... 2015 Bird B Gone, the leader in ... offers a complete line of bird control solutions to address ... New Flu Strains Threaten Pacific, Central and Mississippi Farms , ... , a number of highly pathogenic avian flus in the ... often spread when wild birds enter poultry farms. The USDA ...
(Date:4/24/2015)... Ryadon is a leading manufacturer of custom ... services to complement any custom hardware requirements you may ... be offered on all heavy duty drawer slides ( ... discount - Order 20+: Receive 20% discount , Industries ... Furniture ,Drawer Slides, Inc. ...
(Date:4/24/2015)... 2015 The 1975 have had ... across the globe to theaters, festivals and TV performances. Now ... partnered with their label, Dirty Hit Records, to provide clean ... the newly launched Cadence & Cause website, this ... on vinyl and a signed photo card. Entries from ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... 28 Nutrition 21, Inc.,(Nasdaq: NXXI ), ... consumers manage blood sugar levels, improve cardiovascular health,enhance ... two new,additions to its Iceland Health(R) brand portfolio: ... Plus SLEEP Support.,Formulated with omega-3 fish oil and ...
... Noor came to,the attention of the Battalion Commander of ... Brigade Combat Team through an,unfortunate shooting incident from a ... little girl,s uncle. The initial diagnosis made by Lt.,Col. ... blind,due to a birth defect that resulted in poorly ...
... 28 OrbusNeich today announced that it,has received approval ... R stent in Taiwan., The Genous stent is ... cells (EPCs) circulating in the bloodstream. When,attracted to the ... shown to,quickly form a healthy layer of endothelium that ...
... 28 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... New Drug Application (NDA) for oxybutynin,chloride topical gel ... U.S. Food,and Drug Administration (FDA). Watson is seeking ... hydrochloride for the treatment of,overactive bladder (OAB)., ...
... account for nearly all of the increase in U.S. singleton ... national birth data. , Between 1996 and 2004 there ... 92 percent of those infants were delivered by a cesarean ... of Dimes and the U.S. Centers for Disease Control and ...
... 27 It is estimated that there were ... Did you know that,African-American women have a 50 ... A new campaign, One4One, is empowering women to,help ... increase cervical,cancer education programs for women in multicultural ...
Cached Medicine News:Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 2Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 3Health News:Nutrition 21 Launches Iceland Health(R) Cholesterol Health and Iceland Health(R) Joint Relief Plus SLEEP Support 4Health News:Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger 2Health News:OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 2Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 3Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 4Health News:Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder 5Health News:C-sections a critical factor in preterm birth increase 2
(Date:4/25/2015)... Spain , April 25, 2015  With the ... benefits of precision cranial radiosurgery are now available for ... and sizes. This latest generation stereotactic radiosurgery system for ... imaging technologies, significantly increasing the versatility of Gamma Knife ... the 3 rd ESTRO Forum in ...
(Date:4/24/2015)... -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO, ... from Mylan NV ("Mylan") (NASDAQ: MYL ) to ... $60.00 per share in cash and 2.2 Mylan ordinary ... The Board previously concluded that Mylan,s unsolicited ... and its future growth prospects and was not in ...
(Date:4/24/2015)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, announced the Company will hold a conference call ... to discuss the 1st quarter 2015 results. ... by dialing 1-888-346-3479. International participants should call 1-412-902-4260. Canadian ... joined into the IGI Laboratories, Inc. call. ...
Breaking Medicine Technology:New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4
... England, July 29, 2011 , ... The UK bioindustry has raised over $250m in financing ... any quarter for one year, and the second largest amount raised ... to the financing drought that saw three consecutive quarters below $100m ...
... Health Company (Nasdaq: FHCO ) today announced that ... operating results for the third quarter and first nine months ... Eastern Time (EDT).  The Company expects to report its operating ... other interested parties may participate in the conference call by ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2
... CryoCor CryoBlator Series of Cryoablation Catheters combines ... design with the two-stage cooling system of ... the delivery of cryoenergy to the ablation ... together to create the transmural lesions necessary ...
... is a Microparticle Enzyme Immunoassay (MEIA) for ... HCV recombinant proteins in human serum or ... lithium heparin, sodium citrate and potassium oxalate). ... results and clinical information, may be used ...
... Document Management and Records Management ... to decide how you want to manage your ... all of your critical processes over the ... uses an advanced cross-referencing system ( Para-Links ) ...
... SoftTech Health Lab QMS (Quality Management ... management system built specifically for healthcare ... to help you meet quality management ... your staff has more time to ...
Medicine Products: